TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04010175

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control - Cognitive training in a practitioner's office one time per week
Description: Participant will perform 1-hour cognitive computer based training one time per week in a practitioner's office during 4 months (16 weeks of training = 16 hours of training). This training will include 10 short tasks of increasing difficulty. Performance of these tasks involve cognitive functions such as: executive functions, reasoning, auditive, visual and visuo-spatial memory, speed of processing, short-term memory and working memory. Thus the training aims to exercise all these cognitive functions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental group 1 - Cognitive training in a practitioner's office one time per week and cognitive distance training one time per week
Description: Participant will perform 1-hour cognitive computer based training one time per week in a practitioner's office and one time per week cognitive distance training in her/his place of residence, during 4 months (16 weeks of training = 32 hours of training).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental group 2 - Cognitive training in a practitioner's office one time per week and cognitive distance training four times per week
Description: Participant will perform 1-hour cognitive computer based training one time per week in a practitioner's office and four times per week cognitive distance training in her/his place of residence during 4 months (16 weeks of training = 80 hours of training).
Study: NCT04135495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELX-02
Description: ELX-02 is a small molecule, new chemical entity being developed for the treatment of genetic diseases caused by nonsense mutations. ELX-02 is a eukaroyotic ribosomal selective glycoside (ERSG)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: CFTR potentiator
Study: NCT01641276

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low intensity amplitude-moduled electromagnetic fields
Description: Patients in each arm will be exposed to 30 min of amplitude-moduled low intensity electromagnetic fields only one time.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low intensity amplitude-moduled electromagnetic fields
Description: Patients in each arm will be exposed to 30 min of amplitude-moduled low intensity electromagnetic fields only one time.
Study: NCT03239210

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: 5-HT3 (serotonin receptor type 3) antagonist commonly used to treat nausea and vomiting

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo equivalent
Study: NCT02458846

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Crowded HOTV Acuity Test
Description: This is one of the most sensitive tests of acuity for vision screening of young children. The child is asked to recognize a letter (H,O,T,V) that is surrounded by bars to induce the crowding effects typical of amblyopia. Children were tested monocularly and was required to achieve at least 20/32 in each eye to pass. Children already wearing glasses were tested with their glasses on.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preschool Randot Stereoacuity Test
Description: This is a reliable screening test for stereo depth perception for young children. Children wear polarized stereoglasses and are asked to identify or match shapes that are hiding in the snow, which cannot be perceived if the child has abnormal binocular vision. Children were required to achieve at least 60 arcseconds of disparity to pass. Children already wearing glasses were tested with their glasses worn under the stereo glasses.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plusoptix Autorefractor
Description: Autorefractors are electronic devices that measure refractive errors by focusing a light onto the child's eyes and recording how their reflections from the retina return to the camera. The Plusoptix has been shown to have high sensitivity and specificity in previous research. AAPOS (2013) guidelines were used to determine the referral criteria.
Study: NCT02908867

Intervention type: OTHER
Intervention: Therapeutic Strategies
Description: Using questionnaires (Erectile Function of International Index and American Impairment Scale) and search in public markets using semi structured form
Study: NCT02458846

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Eye Exam
Description: Children who did not pass all three screening tests were referred for full cycloplegic optometry exams, with a parent/guardian present. Optometrists assessed visual history, monocular visual acuity (near \& far), strabismus, binocular function, abnormalities of the anterior segment, and cycloplegic refraction. If the optometrist prescribed glasses, frames were chosen at the time of the exam and the glasses were dispensed either at school (with an optician) or at the optometrist's office.
Study: NCT04215744

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ice water immersion
Description: Ice water immersion of the left hands
Study: NCT00180687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulised Bupivacaine intraperitoneally
Description: Nebulised Marcaine (Bupivacaine)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Nebulised Normal Saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injected Bupivacaine intraperitoneally
Description: Injected Marcaine directly into the peritoneal cavity

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No Intraperitoneal Therapeutics
Description: No Intraperitoneal Therapeutics given
Study: NCT03647475

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Device: Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System Treatment Followed by one-month DAPT
Description: To evaluate the clinical safety of the Resolute Onyx stent with use of one-month DAPT in subjects deemed at high risk for bleeding and/or medically unsuitable for more than one-month DAPT treatment.
Study: NCT04106440

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Application Use
Description: Use applications after initial diagnosis to share information with study team.
Study: NCT02759003

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nightime NIV initiation
Description: In-hospital vs home

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nightime NIV initiation
Description: In-hospital vs home
Study: NCT00427973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib maleate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Peripheral blood was obtained from all patients enrolled for studies of early changes in circulating proangiogenic and proinflammatory molecules and cells. Blood samples were collected in EDTA-containing tubes before and after cediranib therapy on days 1 and 14 of cycle 1. Circulating VEGF, placental growth factor (PlGF), sVEGFR1, basic fibroblast growth factor (bFGF), interleukin (IL)-6, IL-8, transforming growth factor a ((TNF-a), gamma interferon (IFN-g) were measured using multiplex ELISA plates from Meso-Scale Discovery. Hepatocyte growth factor (HGF), insulin-like growth factor 1 (IGF-1), sVEGFR2, angiopoietin 2 (Ang-2), sTie2, soluble c-KIT, carbon anhydrase 9 (CAIX), and stromal cell-derived factor-1a (SDF1a) were measured using ELISA kits from R\&D Systems.
Study: NCT01425788

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Osiris Phleum pratense

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Osiris Phleum pratense
Study: NCT00427973

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: computed tomography (CT) every 8 weeks to evaluate response and progression.
Study: NCT01425788

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Osiris Phleum pratense
Study: NCT00427973

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dynamic contrast-enhanced magnetic resonance imaging
Description: Magnetic resonance imaging (MRI) every 8 weeks to evaluate response and progression.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Blood samples to characterize the steady-state PK of cediranib were drawn from a peripheral vein shortly before patients received the dose on days 8 and 15 of cycle 1 and at the following times relative to dosing on day 1 of cycle 2: 5 min and 1, 2, 4, 6, 8, and 24 hours, with the last sample collected before taking the next daily dose.
Study: NCT02708459

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: surgically inserted Transversus abdominus plane catheter
Description: at end of surgery, a surgeon will insert catheter in Transversus abdominus plane (TAP) between internal oblique muscle and Transversus abdominus muscle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: surgically inserted Transversus abdominus plane catheter
Description: at end of surgery, a surgeon will insert catheter in Transversus abdominus plane (TAP) between internal oblique muscle and Transversus abdominus muscle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous morphine
Description: Boluses of intravenous morphine (2 mg) will be given to patients if Visual analogue scale (VAS) more than 3
Study: NCT03771053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe with simvastatin
Description: ezetimibe 10mg with simvastatin 40mg everyday for 12 months after PCI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: simvastatin 40mg everyday for 12 months after PCI
Study: NCT00267189

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: 1.5 mg bid adjusted in order to achieve a trough level between 3 and 8 ng/mL while in combination with CNI and between 6 and 12 ng/mL after CNI discontinuation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcineurin inhibitors (CNI)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcineurin inhibitors (CNI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate acid (MPA)/ Azathioprine (AZA)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroids

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroids
Study: NCT01160718

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fulvestrant
Description: Arm A: Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days Arm B: Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: selumetinib
Description: AZD6244 75 mg p.o. bid
Study: NCT00777205

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-based peer support
Description: Patients received a) a peer-support manual that outlines self-management and recovery principles and provides peer discussion topics and b) access to a specialized telephone platform that permits free calls to their partners, ready access to mental health staff for back-up and advice on being effective partners, and recorded tips on depression management. They were asked to call their peer partner at least once a week for 24 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Patients received their usual mental health care plus a copy of the Depression Helpbook by Wayne Katon and bi-weekly study mailings with depression management tips.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Usual Care
Description: Patients received their usual mental health care plus a copy of the Depression Helpbook by Wayne Katon and bi-weekly study mailings with depression management tips.
Study: NCT00751621

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IgPro20
Study: NCT00655460

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: glucose control with computer generated recommendations
Description: Insulin dosing will be recommended by the computer tools based on subject glucose values. Bedside clinicians will have the ablity to accept or reject the suggested dose.
Study: NCT02200783

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TripTable
Description: Details of the device previously described, designed to medical operator radioprotection. No changes in radial technique beyond the use of the supportive device will be performed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radial
Description: Standard radial artery catheterization procedure, performed for the purpose of coronary angiography and ad hoc angioplasty if necessary.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral
Description: Standard femoral artery catheterization procedure, performed for the purpose of coronary angiography and ad hoc angioplasty if necessary. The supporting device will be the patient's own body, placing the material above the legs.
Study: NCT03617354

Intervention type: PROCEDURE
Intervention: Total Laparoscopic Hysterectomy
Description: The trainee gynaecologists are undertaking a training program in performing Total Laparoscopic Hysterectomy
Study: NCT05041517

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BOLT + PTC
Description: BOLT is a Brief Online Training (BOLT) for Measurement-Based Care (MBC). Participants in the BOLT condition were subsequently randomized into varying amounts of post-training consultation (PTC).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BOLT + PTC
Description: BOLT is a Brief Online Training (BOLT) for Measurement-Based Care (MBC). Participants in the BOLT condition were subsequently randomized into varying amounts of post-training consultation (PTC).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BOLT + PTC
Description: BOLT is a Brief Online Training (BOLT) for Measurement-Based Care (MBC). Participants in the BOLT condition were subsequently randomized into varying amounts of post-training consultation (PTC).
Study: NCT03555435

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moving Forward On Your Own
Description: Participants in this group will use the online program on their own for 6 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moving Forward with Peer Support
Description: Participants in this group will use the online program on their own for 6 weeks with the support of a peer coach. Peer coaching sessions will consist of 6 15-20 minute sessions one time per week. Sessions will be guided by a Moving Forward Peer Support Manual.
Study: NCT02708459

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous morphine
Description: Boluses of intravenous morphine (2 mg) will be given to patients if Visual analogue scale (VAS) more than 3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous morphine
Description: Boluses of intravenous morphine (2 mg) will be given to patients if Visual analogue scale (VAS) more than 3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupevecaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupevecaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomedine
Study: NCT03770377

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Perturbation to Continuous Perturbation
Description: Manipulate the Movement Planning Period (MPP), by interrupting sensory predictions by removing e-stim during the inter-trial interval (Intermittent Perturbation), followed by a washout/de-adaptation period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Perturbation to Continuous Perturbation
Description: Manipulate the Movement Planning Period (MPP), by interrupting sensory predictions by removing e-stim during the inter-trial interval (Intermittent Perturbation), followed by a washout/de-adaptation period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Perturbation to Continuous Perturbation
Description: Manipulate the Movement Planning Period (MPP), by interrupting sensory predictions by removing e-stim during the inter-trial interval (Intermittent Perturbation), followed by a washout/de-adaptation period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Perturbation to Continuous Perturbation
Description: Manipulate the Movement Planning Period (MPP), by interrupting sensory predictions by removing e-stim during the inter-trial interval (Intermittent Perturbation), followed by a washout/de-adaptation period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Perturbation to Continuous Perturbation
Description: Manipulate the Movement Planning Period (MPP), by interrupting sensory predictions by removing e-stim during the inter-trial interval (Intermittent Perturbation), followed by a washout/de-adaptation period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Perturbation to Intermittent Perturbation
Description: Manipulate the Movement Planning Period (MPP), by keep sensory input about the perturbation constant by maintaining e-stim during the inter-trial interval.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Perturbation to Intermittent Perturbation
Description: Manipulate the Movement Planning Period (MPP), by keep sensory input about the perturbation constant by maintaining e-stim during the inter-trial interval.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Perturbation to Intermittent Perturbation
Description: Manipulate the Movement Planning Period (MPP), by keep sensory input about the perturbation constant by maintaining e-stim during the inter-trial interval.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Perturbation to Intermittent Perturbation
Description: Manipulate the Movement Planning Period (MPP), by keep sensory input about the perturbation constant by maintaining e-stim during the inter-trial interval.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Perturbation to Intermittent Perturbation
Description: Manipulate the Movement Planning Period (MPP), by keep sensory input about the perturbation constant by maintaining e-stim during the inter-trial interval.
Study: NCT04426487

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Progesterone
Description: Intramusculer progesterone
Study: NCT03555435

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Wait
Description: Participants in this group will wait 6 weeks.
Study: NCT04354727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-1252
Description: infusion once weekly
Study: NCT04426487

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Intramusculer progesterone
Study: NCT02256969

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Blephamide

Intervention type: DRUG
Group type: OTHER
Intervention: GenTeal PM Night-Time

Intervention type: DRUG
Group type: OTHER
Intervention: GenTeal PM Night-Time

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Meibomian Gland Probing
Description: For anesthesia, topical 3.5% lidocaine hydrochloride jelly (Akron) was applied directly with sterile cotton-tipped applicator to the lid margin for 3 times every 10 minutes before the procedure. If necessary, 2% lidocaine was injected into the lid margin during the procedure to provide additional comfort. After obtaining adequate anesthesia, the solid stainless steel probes (Maskin® Meibomian Gland Intraductal Probes, Rhein Medical Inc.) were used to probe all the meibomian glands of upper lids of both eyes at the slit lamp. All patients were initially be probed with a 1-mm probe followed by a 2-mm probe for all glands.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Meibomian Gland Probing
Description: For anesthesia, topical 3.5% lidocaine hydrochloride jelly (Akron) was applied directly with sterile cotton-tipped applicator to the lid margin for 3 times every 10 minutes before the procedure. If necessary, 2% lidocaine was injected into the lid margin during the procedure to provide additional comfort. After obtaining adequate anesthesia, the solid stainless steel probes (Maskin® Meibomian Gland Intraductal Probes, Rhein Medical Inc.) were used to probe all the meibomian glands of upper lids of both eyes at the slit lamp. All patients were initially be probed with a 1-mm probe followed by a 2-mm probe for all glands.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sham Meibomian Gland Probing
Description: For anesthesia, topical 3.5% lidocaine hydrochloride jelly (Akron) was applied directly with sterile cotton-tipped applicator to the lid margin for 3 times every 10 minutes before the procedure. If necessary, 2% lidocaine was injected into the lid margin during the procedure to provide additional comfort. The patient's lid margin was touched with the probes without actual probing of the meibomian gland orifices.
Study: NCT00513903

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minimal intervention
Description: Minimal intervention patients will be seen by a clinical pharmacist during the hospitalization period to improve continuity of pharmacy care following hospital discharge.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Intervention
Description: Enhanced intervention patients will be visited in the hospital and will also be called by the clinical pharmacist following discharge to follow-up on any problems that might have developed after discharge.
Study: NCT03347045

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Trimodal Prehab & ERP
Description: 1-hr daily exercise will be completed a total of 5d/week, of which 2 of these sessions are completed through a community fitness center. Following these sessions, the participant will consume a high-protein oral supplement.~Additionally, during the program, participants will be given the option of attending a stress-reduction group and will receive a take-home anxiety-reduction program. They will have access to a physiotherapist, kinesiologist, registered dietitian, and physician throughout the program.~The total length of this program is 8-weeks and is timed to occur in the waiting period between the consent for surgery and operation date.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Prehab; ERP Alone
Description: 1-hr daily exercise with a self-completed home-exercise program. The participant will be given nutritional education material and a take-home anxiety-reduction program. They will be responsible for maintaining a journal of their activity.
Study: NCT00953160

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cutera Radio Frequency Device
Description: Up to three treatments, one pass, dosage range of 15-60 kJ.
Study: NCT04354727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-1252
Description: infusion once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: taken orally twice a day